Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes

Area of Science:

• Endocrinology
• Metabolic Diseases
• Medical Technology

Background:

• Type 1 diabetes mellitus management has advanced with new technologies like insulin pumps and continuous glucose monitoring.
• Traditional multiple daily insulin injections (MDI) remain a common treatment but may not achieve optimal glycemic control for all patients.

Purpose of the Study:

• To compare the efficacy of sensor-augmented pump therapy against multiple daily insulin injections for inadequately controlled type 1 diabetes.
• To evaluate glycemic control, specifically glycated hemoglobin (A1C) levels, in adults and children using these different treatment modalities.

Main Methods:

• A 1-year, multicenter, randomized controlled trial involving 485 patients (adults and children) with type 1 diabetes.
• Patients were randomized to either sensor-augmented pump therapy or injection therapy, receiving recombinant insulin analogues under expert supervision.

Main Results:

• Sensor-augmented pump therapy significantly reduced mean glycated hemoglobin (A1C) from 8.3% to 7.5% over 1 year, compared to a reduction to 8.1% with injection therapy (P<0.001).
• A higher proportion of patients on pump therapy achieved the A1C target (<7%) versus those on injection therapy.
• No significant difference in severe hypoglycemia rates or weight gain was observed between the two groups.

Conclusions:

• Sensor-augmented pump therapy offers a significant advantage in improving A1C levels for both adults and children with type 1 diabetes compared to injection therapy.
• This technology enables a greater number of patients to reach their glycemic targets, indicating its effectiveness in managing inadequately controlled type 1 diabetes.